Alphamab Oncology Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Alphamab Oncology stock has a target of $9.82, which predicts a 34.15% increase from the current stock price of 7.32.

Price Target: $9.82 (+34.15%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$9.82	$9.82	$9.82	$9.82
Change	+34.15%	+34.15%	+34.15%	+34.15%

* Price targets were last updated on Mar 27, 2026.

Analyst Ratings

According to 1 stock analyst, the rating for Alphamab Oncology is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	May '25	Jun '25	Jul '25	Sep '25	Nov '25	Mar '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	1	1	0	0	0	0
Total	2	2	1	1	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Cui Cui Jefferies	Jefferies	Buy Maintains $9.60	Buy	Maintains	$9.60	+31.15%	Mar 27, 2026
Unknown Analyst Sinolink Securities No rating	Sinolink Securities	Buy Maintains $14.30	Buy	Maintains	$14.30	+95.36%	Dec 21, 2025
Unknown Analyst BOCOM International Holdings Company No rating	BOCOM International Holdings Company	Buy Maintains $13.00	Buy	Maintains	$13.00	+77.60%	Dec 14, 2025

Financial Forecast

Revenue This Year

313.90M

from 566.24M

-44.56%

from 566.24M

Revenue Next Year

673.30M

from 313.90M

114.50%

from 313.90M

EPS This Year

-0.14

from -0.12

EPS Next Year

-0.06

from -0.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	146.02M	166.85M	218.77M	640.08M	566.24M	313.90M
Revenue Growth	-	14.26%	31.12%	192.58%	-11.54%	-44.56%
Gross Profit	142.99M	122.64M	163.54M	579.77M	502.69M	282.51M
Gross Margin	97.93%	73.50%	74.75%	90.58%	88.78%	90.00%
Operating Income	-415.62M	-432.37M	-323.33M	101.01M	-153.29M	-388.20M
Net Income	-412.42M	-325.72M	-210.59M	166.34M	-113.94M	200.60M
EPS	-	-	-	-	-0.12	-0.14
Free Cash Flow	-330.88M	-332.02M	-186.64M	139.12M	-106.62M	243.00M
No. Analysts	-	-	-	-	-	1

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue	2026	2027	2028
High	313.9M
Avg	313.9M
Low	313.9M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-44.6%
Avg	-44.6%
Low	-44.6%

EPS Forecast

EPS	2026	2027	2028
High	-0.14
Avg	-0.14
Low	-0.14

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-